YTYu Tian

Yu Tian

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yu Tian has a total of 58 co-authors. Here are the top co-authors by number of shared publications:

  • Qingquan Luo

    Department of Thoracic Surgical Oncology, Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

    10 shared publications
  • Dongfang Dai

    The Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing, Jiangsu, P.R. China

    7 shared publications
  • Hanbo Pan

    Department of Thoracic Surgical Oncology, Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, 241 Huaihai West Road, Shanghai, 200030, China.

    7 shared publications
  • Hongda Zhu

    Department of Thoracic Surgical Oncology, Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, 200300, China

    7 shared publications
  • Hui Hou

    Drug Discovery and Design Center, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China

    7 shared publications
  • Hui Wang

    Department of Thoracic Surgical Oncology, Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, P.R. China

    7 shared publications

Latest Publications

  • Lobectomy Versus Sub-lobectomy for Clinical Stage IA (≤2 cm) Lung Squamous Cell Carcinoma with Tumour Spread through Air Spaces: A Multi-Centre Retrospective Study

    by Hanbo Pan, Hang Chen, Zhen Ge, Yu Tian, Weicheng Kong, Wanyu Li, Junwei Ning, Zhiyuan Bao, Zhizhuo Dai, Zhongjie Chen, et al.

    Objectives: The efficacy of sub-lobectomy for clinical IA (tumours ≤2 cm) lung squamous cell carcinoma with tumour spread through air spaces (STAS) remains unknown. This study compares long-term survival outcomes between sub-lobectomy and lobectomy, aiming to offer pivotal evidence for optimizing resection strategies for clinical IA STAS-positive squamous cell carcinoma patients. Methods: Consecutive clinical IA STAS-positive squamous cell carcinoma patients undergoing surgery between 2010 and 2020 at 7 high-volume institutions across 5 Chinese cities were retrospectively reviewed. The primary end-point was overall survival, and the secondary end-point was recurrence-free survival. Propensity-score matching was employed to mitigate selection bias. Results: A total of 870 patients were included, and propensity-score matching yielded 476 and 238 cases in the lobe and sub-lobe groups, respectively. Over an estimated median follow-up of 6.51 years, lobectomy significantly improved overall survival (hazard ratio [95% confidence interval] = 0.598 [0.447-0.761], P < .001) and recurrence-free survival (hazard ratio [95% confidence interval] = 0.572 [0.449-0.733], P < .001), and reduced postoperative mortality (30.7% vs 40.3%, P = .010) and recurrence (39.3% vs 55.0%, P < .001) incidences compared to sub-lobectomy. Further subgroup analysis revealed that lobectomy improved survival outcomes over sub-lobectomy in younger (age <70 years) and clinical IA2 sub-cohorts, while the 2 approaches yielded comparable survival outcomes for elderly (age ≥70 years) and clinical IA1 sub-cohorts. Conclusions: Lobectomy improved survival outcomes over sub-lobectomy for clinical IA STAS-positive squamous cell carcinoma and thus might be preferred for clinical IA squamous cell carcinoma patients with highly suspected STAS. The prognostic benefits of lobectomy may be discriminated by age and clinical stage.


  • Open Access

    Ultra-remote robot-assisted right upper lobectomy between the Shanghai and Kashi Prefectures: a case report

    by Yu Tian, Huibin Lv, Adilijiang Jumai, Tuersun Tuerhong, Lihong Zhuang, Jia Huang, Jiantao Li, Peiji Lu, Guorong Tao, Yoshikane Yamauchi, et al.

    Background: Robot-assisted thoracic surgery has been shown to have several advantages over conventional surgery. As mobile communication technology and surgical robotic devices in China continue to progress rapidly, the conditions for performing remote surgery have been optimized. Consequently, informatized and remote advanced medical cooperation is becoming a new direction for supporting the medical development of border regions and promoting the equitable distribution of medical resources in China. Case Description: In this case, a 53-year-old female patient in Kashi was admitted with a mixed ground-glass lesion in the right upper lobe. The size and density of the lesion were found to be increasing progressively. After a comprehensive multidisciplinary team consultation, the patient was clinically diagnosed with early stage lung cancer. The patient gave informed consent to undergo remote robot-assisted right upper lobectomy and lymph node dissection, which was performed on July 13, 2024 between Shanghai and Kashi using a dedicated network and 5G mobile communication. The procedure was successfully conducted with an average delay of 100 ms and no connection interruptions. Pathology and immunohistochemistry confirmed invasive mucinous adenocarcinoma (T1aN0M0). Postoperative imaging showed good lung re-expansion; the patient had an ideal recovery and was discharged smoothly. Conclusions: We reported the first case in which a remote robot-assisted lobectomy was performed using a robotic surgical system, 5G technology, and corresponding procedures. More cohorts or clinical studies need to be conducted to further clarify the guidelines and promote the application of remote thoracic surgery.


  • Perioperative immune checkpoint blockades improve prognosis of resectable non-small cell lung cancer

    by Yu Tian, Zhichao Liu, Hanbo Pan, Hongda Zhu, Ningyuan Zou, Long Jiang, Ziming Li, Jia Huang, Yingjie Hu, Qingquan Luo

    OBJECTIVES: Immune checkpoint blockades (ICB) have been proven to improve prognosis of non-small cell lung cancer in the neoadjuvant setting, while whether its perioperative use could bring extra benefit remained unidentified. We aimed to demonstrate the prognostic benefit of perioperative ICB over preoperative-only use and investigate who could benefit from this ‘sandwich ICB therapy’. METHODS: Patients undergoing neoadjuvant therapy followed by surgery from 2018 to 2022 were retrospectively reviewed, and were divided into 4 groups based on the perioperative regimens: pre-ICB + post-computed tomography (CT), pre-ICB-only, pre-CT + post-ICB and pre-CT-only. Treatment-related adverse events, surgical outcomes, therapeutic response, recurrence-free survival and overall survival were compared. RESULTS: Of 214 enrolled patients with preoperative therapy, 108 underwent immunochemotherapy and 106 underwent platinum-based chemotherapy. Compared with preoperative chemotherapy, preoperative immunochemotherapy was demonstrated with significantly higher major pathologic response (57/108 vs 12/106) and pathologic complete response (35/108 vs 4/106) rates with comparable adverse events. Regarding survival, perioperative ICB significantly improved the recurrence-free survival [versus pre-CT-only hazard ratio (HR) 0.15; 95% CI 0.09–0.27; versus pre-ICB-only HR 0.36; 95% CI 0.15–0.88] and overall survival (versus pre-CT-only HR 0.24; 95% CI 0.08–0.68). In patients without major pathologic response, perioperative ICB was observed to decrease the risk of recurrence (HR 0.31; 95% CI 0.11–0.83) compared with preoperative ICB, and was an independent prognostic factor (P < 0.05) for recurrence-free survival. CONCLUSIONS: Perioperative ICB showed promising efficacy in improving pathological response and survival outcomes of resectable non-small cell lung cancer. For patients without major pathologic response after resection followed by preoperative ICB, sequential ICB treatment could be considered.


  • Open Access

    Data from DNA-PK–Mediated Cytoplasmic DNA Sensing Stimulates Glycolysis to Promote Lung Squamous Cell Carcinoma Malignancy and Chemoresistance

    by Hui Wang, Yanyang Zhang, Yu Tian, Wanlin Yang, Yan Wang, Hui Hou, Hanbo Pan, Siyu Pei, Hongda Zhu, Zenan Gu, et al.

    Detection of cytoplasmic DNA is an essential biological mechanism that elicits IFN-dependent and immune-related responses. A better understanding of the mechanisms regulating cytoplasmic DNA sensing in tumor cells could help identify immunotherapeutic strategies to improve cancer treatment. Here we identified abundant cytoplasmic DNA accumulated in lung squamous cell carcinoma (LUSC) cells. DNA-PK, but not cGAS, functioned as a specific cytoplasmic DNA sensor to activate downstream ZAK/AKT/mTOR signaling, thereby enhancing the viability, motility, and chemoresistance of LUSC cells. DNA-PK–mediated cytoplasmic DNA sensing boosted glycolysis in LUSC cells, and blocking glycolysis abolished the tumor-promoting activity of cytoplasmic DNA. Elevated DNA-PK–mediated cytoplasmic DNA sensing was positively correlated with poor prognosis of human patients with LUSC. Targeting signaling activated by cytoplasmic DNA sensing with the ZAK inhibitor iZAK2 alone or in combination with STING agonist or anti-PD-1 antibody suppressed the tumor growth and improved the survival of mouse lung cancer models and human LUSC patient-derived xenografts model. Overall, these findings established DNA-PK–mediated cytoplasmic DNA sensing as a mechanism that supports LUSC malignancy and highlight the potential of targeting this pathway for treating LUSC.Significance:DNA-PK is a cytoplasmic DNA sensor that activates ZAK/AKT/mTOR signaling and boosts glycolysis to enhance malignancy and chemoresistance of lung squamous cell carcinoma.

  • Open Access

    Supplementary Figure and figure legends from DNA-PK–Mediated Cytoplasmic DNA Sensing Stimulates Glycolysis to Promote Lung Squamous Cell Carcinoma Malignancy and Chemoresistance

    by Hui Wang, Yanyang Zhang, Yu Tian, Wanlin Yang, Yan Wang, Hui Hou, Hanbo Pan, Siyu Pei, Hongda Zhu, Zenan Gu, et al.

    Supplementary Figure and figure legends

  • Open Access

    Supplementary Figure and figure legends from DNA-PK–Mediated Cytoplasmic DNA Sensing Stimulates Glycolysis to Promote Lung Squamous Cell Carcinoma Malignancy and Chemoresistance

    by Hui Wang, Yanyang Zhang, Yu Tian, Wanlin Yang, Yan Wang, Hui Hou, Hanbo Pan, Siyu Pei, Hongda Zhu, Zenan Gu, et al.

    Supplementary Figure and figure legends

  • Open Access

    Data from DNA-PK–Mediated Cytoplasmic DNA Sensing Stimulates Glycolysis to Promote Lung Squamous Cell Carcinoma Malignancy and Chemoresistance

    by Hui Wang, Yanyang Zhang, Yu Tian, Wanlin Yang, Yan Wang, Hui Hou, Hanbo Pan, Siyu Pei, Hongda Zhu, Zenan Gu, et al.

    Detection of cytoplasmic DNA is an essential biological mechanism that elicits IFN-dependent and immune-related responses. A better understanding of the mechanisms regulating cytoplasmic DNA sensing in tumor cells could help identify immunotherapeutic strategies to improve cancer treatment. Here we identified abundant cytoplasmic DNA accumulated in lung squamous cell carcinoma (LUSC) cells. DNA-PK, but not cGAS, functioned as a specific cytoplasmic DNA sensor to activate downstream ZAK/AKT/mTOR signaling, thereby enhancing the viability, motility, and chemoresistance of LUSC cells. DNA-PK–mediated cytoplasmic DNA sensing boosted glycolysis in LUSC cells, and blocking glycolysis abolished the tumor-promoting activity of cytoplasmic DNA. Elevated DNA-PK–mediated cytoplasmic DNA sensing was positively correlated with poor prognosis of human patients with LUSC. Targeting signaling activated by cytoplasmic DNA sensing with the ZAK inhibitor iZAK2 alone or in combination with STING agonist or anti-PD-1 antibody suppressed the tumor growth and improved the survival of mouse lung cancer models and human LUSC patient-derived xenografts model. Overall, these findings established DNA-PK–mediated cytoplasmic DNA sensing as a mechanism that supports LUSC malignancy and highlight the potential of targeting this pathway for treating LUSC.Significance:DNA-PK is a cytoplasmic DNA sensor that activates ZAK/AKT/mTOR signaling and boosts glycolysis to enhance malignancy and chemoresistance of lung squamous cell carcinoma.

  • DNA-PK–Mediated Cytoplasmic DNA Sensing Stimulates Glycolysis to Promote Lung Squamous Cell Carcinoma Malignancy and Chemoresistance

    by Hui Wang, Yanyang Zhang, Yu Tian, Wanlin Yang, Yan Wang, Hui Hou, Hanbo Pan, Siyu Pei, Hongda Zhu, Zenan Gu, et al.

    Detection of cytoplasmic DNA is an essential biological mechanism that elicits IFN-dependent and immune-related responses. A better understanding of the mechanisms regulating cytoplasmic DNA sensing in tumor cells could help identify immunotherapeutic strategies to improve cancer treatment. Here we identified abundant cytoplasmic DNA accumulated in lung squamous cell carcinoma (LUSC) cells. DNA-PK, but not cGAS, functioned as a specific cytoplasmic DNA sensor to activate downstream ZAK/AKT/mTOR signaling, thereby enhancing the viability, motility, and chemoresistance of LUSC cells. DNA-PK–mediated cytoplasmic DNA sensing boosted glycolysis in LUSC cells, and blocking glycolysis abolished the tumor-promoting activity of cytoplasmic DNA. Elevated DNA-PK–mediated cytoplasmic DNA sensing was positively correlated with poor prognosis of human patients with LUSC. Targeting signaling activated by cytoplasmic DNA sensing with the ZAK inhibitor iZAK2 alone or in combination with STING agonist or anti-PD-1 antibody suppressed the tumor growth and improved the survival of mouse lung cancer models and human LUSC patient-derived xenografts model. Overall, these findings established DNA-PK–mediated cytoplasmic DNA sensing as a mechanism that supports LUSC malignancy and highlight the potential of targeting this pathway for treating LUSC. Significance: DNA-PK is a cytoplasmic DNA sensor that activates ZAK/AKT/mTOR signaling and boosts glycolysis to enhance malignancy and chemoresistance of lung squamous cell carcinoma.